Claris Lifesciences has moved higher 5% to Rs 197 in noon deals on hopes the pharmaceutical would soon announce a dividend payout.
“The board of directors of the company will meet on February 23, 2013, to consider and recommend of dividend if any, for the year ended December 31, 2012,” Claris Lifesciences said in a statement.
The company recently sold its infusion business, on a slump basis, for Rs 1,050 crore said that out of the net proceeds it plans to utilize Rs 300 crore towards a special dividend or buyback of shares.
Meanwhile, the board will also consider and take on record the annual audited financial results of the company for the year ended December 31, 2012, it added.
The stock opened at Rs 188 and hit a high of Rs 198 on BSE. Around 33,000 shares have already changed hands on the counter till 1332 hours against an average 37,000 shares that were traded daily in past two weeks.
“The board of directors of the company will meet on February 23, 2013, to consider and recommend of dividend if any, for the year ended December 31, 2012,” Claris Lifesciences said in a statement.
The company recently sold its infusion business, on a slump basis, for Rs 1,050 crore said that out of the net proceeds it plans to utilize Rs 300 crore towards a special dividend or buyback of shares.
Meanwhile, the board will also consider and take on record the annual audited financial results of the company for the year ended December 31, 2012, it added.
The stock opened at Rs 188 and hit a high of Rs 198 on BSE. Around 33,000 shares have already changed hands on the counter till 1332 hours against an average 37,000 shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%